Proteins behind breast cancer growth identified

Image
Press Trust of India Washington
Last Updated : Aug 21 2013 | 2:57 PM IST
Scientists have identified two proteins as prime suspects in the proliferation of breast cancer, paving way for new drug targets to fight the deadly disease.
The study by an international consortium of researchers from Rice University, the University of North Texas, Denton (UNT); the University of California, San Diego (UCSD); and the Hebrew University of Jerusalem, may offer a path to therapies that could slow or stop tumours from developing.
The research found that reducing the expression of a pair of proteins known as NEETs - NAF-1 and mitoNEET - significantly reduced cancer cell proliferation and breast cancer tumour size.
The research stemmed from a recent Rice's Center for Theoretical Biological Physics (CTBP) study of the shape and functions of one of the proteins, mitoNEET. The other protein, NAF-1, is closely related to mitoNEET.
CTBP co-director Jose Onuchic, a biological physicist at Rice, said the new study was triggered by the team's recognition of a connection between NEETs and reduced rates of breast cancer among women who take a diabetes drug that targets mitoNEET.
"NEET proteins play a key role in the overall stress response of cells," Onuchic said.
"Anytime you stress a system, these proteins are there to help, but in cases where cells are overcome by stress, NEETs can become highly overexpressed. That's what drew our interest in a potential connection to cancer," he said.
NEET proteins transport iron molecules or iron sulfur clusters inside cells. The proteins naturally adhere to the outer surface of the mitochondria, the "power plant" that supplies cells with chemical energy.
Experiments found an overabundance of both mitoNEET and NAF-1 in breast cancer cells. Moreover, the team found a direct correlation between NEET protein levels and the overall progression of the disease.
The results suggest that the overabundance of NEETs is a factor in the runaway growth of cancer cells, and that would make NEETs a prime target for anticancer drugs.
The research is published in the Proceedings of the National Academy of Sciences.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 21 2013 | 2:57 PM IST

Next Story